Abstract
Malignant pleural effusion (MPE) is the accumulation of fluid in the pleural cavity due to cancer. Currently it's incurable. Stimulation of MHC I pathway could be clinically exploited to promote anticancer immune response.
We developed a methodology to establish cancer cell cultures derived from MPE specimens. These cells are phenotypically stable and able to form tumour-spheres. And they exhibited non-synchronized proliferation and displayed different response rate to the drugs, which reflected interpatient heterogeneity. Among these cell cultures, MESO044 and MESO392 were treated with 6 chemotherapeutic drugs together with first line chemotherapy regime: cisplatin plus pemetrexed (cispem). Then MHC I antigen presentation pathway change was examined by QRT-PCR and flow cytometry. The data showed that bortezomib displayed the most significant upregulation effect of MHC I pathway components expression on both two cell cultures. Moreover, we co-cultured the cancer cells with SSX-2 specific CD8+ T cells after treated with drugs. The data showed that the killing capacity of CD8+ T cells were induced at various levels. Furthermore, autologous CD8+ T cells would be exploited to this research.
In summary, our findings suggest that the ex vivo culture of patient derived cancer cells could be a prospective platform to investigate personalized chemo-immunotherapy strategies for MPE.
Footnotes
Cite this article as ERJ Open Research 2022; 8: Suppl. 8, 16.
This article was presented at the 2022 ERS Lung Science Conference, in session “Poster Session 2”.
This is an ERS Lung Science Conference abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2022